Analysts forecast that PRA Health Sciences Inc (NASDAQ:PRAH) will report $717.71 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for PRA Health Sciences’ earnings. The highest sales estimate is $721.75 million and the lowest is $708.50 million. PRA Health Sciences reported sales of $763.31 million during the same quarter last year, which indicates a negative year over year growth rate of 6%. The company is expected to issue its next quarterly earnings results on Wednesday, July 29th.
According to Zacks, analysts expect that PRA Health Sciences will report full-year sales of $3.06 billion for the current fiscal year, with estimates ranging from $2.98 billion to $3.13 billion. For the next year, analysts expect that the business will report sales of $3.38 billion, with estimates ranging from $3.18 billion to $3.57 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow PRA Health Sciences.
PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Thursday, April 30th. The medical research company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.01 by $0.04. PRA Health Sciences had a net margin of 7.66% and a return on equity of 27.59%. The firm had revenue of $783.71 million for the quarter, compared to the consensus estimate of $749.61 million. During the same period in the prior year, the firm earned $1.10 EPS. The company’s revenue was up 8.5% compared to the same quarter last year.
In related news, CFO Michael J. Bonello sold 3,672 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $87.97, for a total transaction of $323,025.84. Following the transaction, the chief financial officer now owns 23,328 shares in the company, valued at $2,052,164.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.30% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. Fortis Advisors LLC bought a new position in PRA Health Sciences in the first quarter valued at about $34,000. Squar Milner Financial Services LLC increased its position in shares of PRA Health Sciences by 172.8% during the 4th quarter. Squar Milner Financial Services LLC now owns 431 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 273 shares during the last quarter. C M Bidwell & Associates Ltd. bought a new position in shares of PRA Health Sciences in the 4th quarter worth approximately $52,000. Fifth Third Bancorp boosted its holdings in shares of PRA Health Sciences by 14.5% in the first quarter. Fifth Third Bancorp now owns 1,079 shares of the medical research company’s stock worth $90,000 after buying an additional 137 shares during the last quarter. Finally, Cullen Frost Bankers Inc. grew its position in PRA Health Sciences by 150.1% during the fourth quarter. Cullen Frost Bankers Inc. now owns 1,023 shares of the medical research company’s stock valued at $114,000 after buying an additional 614 shares during the period. Institutional investors own 97.29% of the company’s stock.
Shares of NASDAQ PRAH traded up $0.77 on Monday, reaching $97.46. 192,511 shares of the company’s stock traded hands, compared to its average volume of 494,508. PRA Health Sciences has a 12 month low of $58.67 and a 12 month high of $113.10. The business’s 50 day simple moving average is $87.69 and its two-hundred day simple moving average is $97.96. The company has a market cap of $6.16 billion, a price-to-earnings ratio of 26.63 and a beta of 1.09. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 1.30.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: Support Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.